At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based CFO’ operating in the Health Care space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Chuck Carelli
CFO of Flagship Pioneering
Chuck Carelli, CPA, joined Flagship Ventures in 2009 with 16 years of experience in financial accounting, reporting and management. After obtaining his CPA license while working in the Boston office of Deloitte & Touche, Chuck spent 13 years in various senior financial accounting and management roles at three Massachusetts-based publicly traded biotech companies. From 2004 until joining Flagship, he served in various senior financial roles with EXACT Sciences, most recently as Chief Financial Officer. Previously he was with Alkermes, Inc. serving first as Controller then as Director of Finance. He also served as Accounting Manager and then Director of Accounting at Creative BioMolecules. As CFO, Chuck is responsible for all of Flagship Ventures’ financial and tax reporting, cash flow management, fund audits, and financial administration, as well as the financial operations of Flagship’s VentureLabsTM unit. Chuck holds a BA in Accounting from Assumption College.
Follow Chuck Carelli:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Sravan K. Emany
SVP & Chief Financial Officer of Ironwood Pharmaceuticals
Sravan K. Emany is Chief Financial Officer at Ironwood. Before joining the company in 2021, Mr. Emany served as the Corporate Vice President, Commercial Excellence and Chief Strategy Officer at Integra Lifesciences Holdings Corporation, where he was responsible for the Company’s commercial support functions and led the development of their corporate strategy. Prior to Integra, Mr. Emany was at Bank of America for ten years and held roles of increasing responsibility within the Mergers & Acquisitions (M&A) business, ultimately serving as a Managing Director of the M&A group. Mr. Emany began his career working at several well-respected banking institutions including Morgan Stanley and Goldman Sachs. Mr. Emany has a B.A. in international relations and an M.A. in international relations and international economics, both from Johns Hopkins University.
Follow Sravan K. Emany:
About Ironwood Pharmaceuticals: Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Jeanne Henry
CFO of Excel Venture Management
Jeanne joined the Excel team in 2009 and brings more than 18 years of venture capital financial management and reporting experience to the team. Previously, Jeanne was CFO and most recently COO with Atlas Venture, an international venture firm. Earlier she was an Audit Manager with Coopers & Lybrand (now PricewaterhouseCoopers). Jeanne holds a B.A. from the University of New Hampshire, an MBA from the University of Illinois, Chicago and is a Certified Public Accountant. She is a member of the AICPA, the M.A. Society of CPA’s, and a former Board member of the Private Equity CFO Association.
Follow Jeanne Henry:
About Excel Venture Management: Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond.
Kevin Gillis
CFO / Partner of Third Rock Ventures
Kevin Gillis joined Third Rock Ventures in 2008 and oversees the operational, financial and administrative aspects of the firm. He also directs and oversees the initial operational activities for our portfolio companies. Kevin has approximately 20 years of financial experience, successfully designing, overseeing and managing the financial operations for both newly emerging and established biotech companies. Prior to joining Third Rock Ventures, Kevin was Vice President of Finance at Coley Pharmaceutical Group, supporting the company’s successful initial public offering in 2005 and overseeing the finances related to the company’s acquisition by Pfizer in 2008. Prior to Coley, Kevin served in a number of senior finance roles at Millennium Pharmaceuticals and The Coca-Cola Company. Kevin holds an MBA from Bentley University and a BA from Brandeis University.
Follow Kevin Gillis:
About Third Rock Ventures: Third Rock Ventures invests in transformational life science companies that show high growth potential
Ommer Chohan
Chief Financial Officer of Atlas Venture
Ommer Chohan joined Atlas in 2015 and servers as the firm’s Chief Financial Officer. He oversees the firm’s financial, legal, and operations functions. Prior to joining Atlas, Ommer was CFO/COO at Summerhill Venture Partners. Ommer joined Summerhill in 2006 and was part of the original team that spun out the firm from Bell Canada. At Summerhill Ommer was responsible for the finance, IT, and administrative functions in addition to providing financial and legal support to the investment team. Prior to Summerhill, Ommer was the VP-Finance at First Asset Management Inc. (acquired by Affiliated Managers Group), a holding company with equity interests in several leading Canadian asset management firms. Ommer received his BA-Honours, Specialist in Management from the University of Toronto, his MBA from the Johnson School at Cornell University, and earned his CPA (Ontario) while at PricewaterhouseCoopers.
Follow Ommer Chohan:
About Atlas Venture: Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Dan Tempesta
Chief Financial Officer and EVP of Nuance Communications
Dan Tempesta assumed the role of executive vice president and Chief Financial Officer of Nuance in July 2015. Since joining Nuance in 2008, Dan has held several senior finance roles, having most recently served as Nuance’s Chief Accounting Officer, Corporate Controller, and Senior Vice President of Finance. Dan brings more than 20 years of experience to the role, including extensive financial and operational experience with publicly-held companies and accounting firms. During his time at Nuance, Dan has led the majority of Nuance’s finance and accounting operations, as well as tax, treasury, order management, and internal control activities. He received an accounting degree from the Isenberg School of Management at the University of Massachusetts, Amherst.
Follow Dan Tempesta:
About Nuance Communications: Nuance Communications provides conversational AI innovations that bring intelligence to everyday work and life.
Peter Aranow
Chief Financial Officer of Respiratory Motion
Mr. Aranow is the Chairman of Boynton Angels, a Worcester investor group that invests in start-up companies. Peter Aranow has spent 30 years in finance. For 17 years he was in the investment banking department of Bear Stearns & Co., where he worked on debt and equity financings, mergers and acquisitions, and was the investment banker responsible for Bear Stearns’ initial public offering. For the following 13 years he served as chief financial officer for a number of public and privately-owned companies, including an Internet advertising company and the New York City Off-Track Betting Corporation. Mr. Aranow holds an BA from Harvard College and an MBA from Harvard Business School.
Follow Peter Aranow:
About Harvard Business School Community Action Partners, Off Track Betting New York, Respiratory Motion: Respiratory Motion ExSpiron is FDA and CE Mark cleared and non-invasively measures minute ventilation, the fundamental unit of breathing.
John Withee
CFO of New Balance
Mr. John Withee has been Chief Financial Officer and Executive Vice President of New Balance Athletic Shoe, Inc. since February 2005. Mr. Withee began his career with New Balance as the Manufacturing Controller in 1989. During his tenure he has been instrumental in guiding business during substantial growth periods and he continues to counsel in both the financial and the operational aspects of the business. He holds a Bachelor of Science from the University of Maine
Follow John Withee:
About New Balance: New Balance is an American multinational corporation based in the Brighton neighborhood of Boston.
Daniel Geffken
Interim Chief Financial Officer of CalciMedica
Daniel E. Geffken is the founder and managing director of Danforth Advisors, a consulting firm providing administrative, strategic and operational support to life science companies. He has more than 20 years of experience in the life science industry, with companies ranging from early startups to publicly-traded companies with over $1 billion market capitalizations. Previously, he served as chief operating officer or chief financial officer of four publicly-traded and four privately-held companies, in addition to his consulting clients, and was interim chief executive officer of a medical device company. In these roles, he held management responsibility for finance, accounting, human resources, investor/public relations, facilities, legal, intellectual property and manufacturing functions. Mr. Geffken has raised more than $700 million in equity and debt securities, including a $132 million private placement that was, at the time, the largest private investment in public equity (PIPE) in biotechnology history. Previous to these roles, Mr. Geffken was a principal in a private equity firm, and prior to that position was a certified public accountant (CPA) at KPMG. Mr. Geffken holds a master’s degree in business administration from Harvard Business School and a bachelor’s degree in economics from The Wharton School at the University of Pennsylvania.
Follow Daniel Geffken:
About AnTolRx, Apic Bio, CalciMedica, Danforth Advisors, Danforth Diamond, DermBiont, Elicio Therapeutics, ProMIS Neurosciences, Vigeo Therapeutics, Zikani Therapeutics: CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.
Jeff Poulton
Chief Financial Officer of Alnylam Pharmaceuticals
Follow Jeff Poulton:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Gaurav Agarwal
Chief Financial Officer of emids
Gaurav is in charge of overseeing the company’s finance, legal and secretarial functions.He is an expert in Mergers & Acquisitions, Finance, Investor Relations, Negotiation, Financial analysis, and other related areas. Gaurav works closely with all other executives to build long term and short term strategy and help implement them while adopting the best standards in financial and operational discipline. He is a Chartered Accountant from India and Certified Public Accountant from USA.
Follow Gaurav Agarwal:
About emids: Emids is a consulting firm that provides IT and business process management solutions to the healthcare industry.
Fritz von Mering
Chief Financial Officer of Goodpath
Follow Fritz von Mering:
About Goodpath, Miles River Management: Goodpath is a telehealth startup focused on improve helping people managing common health conditions.
Fred Driscoll
Chief Financial Officer of Flexion Therapeutics
Fred Driscoll has more than 20 years of experience in financial management of life sciences companies, most recently as the Chief Financial Officer at Flexion Therapeutics, Inc., where he spearheaded an initial public offering in 2014. Prior to joining Flexion, he served as Chief Financial Officer at Novavax, Inc. from 2009 to 2013. From 2008 to 2009, Fred Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. Prior to serving as Chief Executive Officer of Genelabs he was the Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Fred Driscoll served as Chief Executive Officer at OXiGENE, Inc., where he also served as Chairman of the Board and Audit Committee Chair. He was also a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016. Fred Driscoll earned a B.S. in accounting and finance from Bentley University. He is a member of the board of directors of Cellectar Biosciences, Inc., MEI Pharma, Inc. and NantKwest, Inc.
Follow Fred Driscoll:
About Flexion Therapeutics: Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.
Frank Reynolds
Chairman of the Board, CEO, CFO, CSO & Co-Founder of PixarBio
Follow Frank Reynolds:
About PixarBio: PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products.
Kam Unninayar
CFO of Tetraphase Pharmaceuticals
Follow Kam Unninayar:
About Tetraphase Pharmaceuticals: Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.
Genevieve Barnard
CFO & Co-Founder of MDaaS Global
Genevieve Barnard is the CFO and Co- founder of MDaaS. She used to be the associate director of associate director at Kletjian Foundation. Genevieve earned her MBA at Massachusetts Institute of Technology – Sloan School of Management.
Follow Genevieve Barnard:
About MDaaS Global: MDaaS Global operates tech-enabled diagnostic centers in clinically-underserved communities.
Gregory Weaver
Chief Financial Officer of Eloxx
Greg Weaver joined PLI as CFO in November 2015. Greg is an experienced CFO and board director, having served in executive positions with biopharma companies in the US and Europe. Most recently he served as CFO and board director with Oryzon Genomics in Boston and Barcelona, and previously has served as CFO with the following Nasdaq-listed public biotech companies: Fibrocell, Celsion, Poniard, Sirna, Nastech, and ILEX. Greg currently serves on the boards of public biotech companies Egalet, and Atossa Genetics. Greg has led the raise of over US$800 million in various financing transactions throughout his career, and has led companies through IPO, drug development, and revenue growth, while positioning a number of companies for successful acquisition. Greg began his career as a CPA with Arthur Andersen, with an MBA from Boston College and BS in accounting from Trinity University.
Follow Gregory Weaver:
About Eloxx: Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates.
Nikita Shah
President & CFO of Nivien Therapeutics
Follow Nikita Shah:
About General Biotechnologies, Nivien Therapeutics: Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
Michael Baker
CFO of Cloud 9
Michael Baker is CFO at Cloud9.
Follow Michael Baker:
About Cloud 9: Cloud 9 creates a dual treatment solution for behavioral healthcare prevention and intervention.
Ian C. Sanderson
CFO of Nimbus Therapeutics
Follow Ian C. Sanderson:
About Boston Pharmaceuticals, Nimbus Therapeutics: Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Daniella Beckman
CFO of Tango Therapeutics
Daniella Beckman has served as the senior vice president, chief financial officer and treasurer of Idenix since March 2012 and the vice president, chief financial officer and treasurer since June 2011. Daniella Beckman served as the interim chief financial officer and treasurer of Idenix from October 2010 to June 2011 and as the corporate controller of Idenix from March 2008 to October 2010. Before joining Idenix, Daniella Beckman held positions at Coley Pharmaceutical Group, most recently as corporate controller. Prior to Coley, Daniella Beckman also held positions at Biogen Idec from September 2004 through March 2006 as well as PricewaterhouseCoopers from September 2000 through September 2004. Daniella Beckman holds a B.A. from Boston University and is also a Certified Public Accountant (CPA).
Follow Daniella Beckman:
About Tango Therapeutics: Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Bruce Tiedemann
Partner / CFO of Boston Millennia Partners
Bruce is a founder of Tiedemann & Company, an independent certified public accounting firm. He has also served as part-time Chief Financial Officer or Controller of several start-up venture funded companies. His professional experience includes over 20 years of public accounting experience.
Follow Bruce Tiedemann:
About Boston Millennia Partners: Boston Millennia Partners provides private equity financing to high growth companies in the healthcare and business services industries.
Chip Catlin
Senior Vice President and Chief Financial Officer of Celldex Therapeutics
Chip Catlin joined our board of directors in September 2018. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc. Chip Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions adding substantial long term value for the company. Prior to Celldex, Chip Catlin held senior financial and operational positions with biopharma companies Endogen, Inc. and Repligen Corporation. Chip Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College. He is also a certified public accountant. Chip Catlin’s more than 22 years of experience as a senior financial officer of public biopharmaceutical companies make him an ideal addition to our board of directors.
Follow Chip Catlin:
About Celldex Therapeutics: Celldex is a clinical stage company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases.
Grayson Allen
CFO/COO & Co-Founder of RevBio
Grayson oversees the financial planning and reporting function as Interim CFO at Maxwell Health, and is also involved in strategic and tactical matters related to Maxwell’s continued growth. Previously, Grayson served as the CFO of a venture-backed technology company where he led a team which oversaw all financial planning and reporting, accounting, information technology, and human resources functions at the company. He played a key role in raising more than $60 million in venture capital and implemented the infrastructure necessary for rapid growth. Grayson also served as CFO for a private equity owned company engaged in the design and manufacture of bridge cranes, gantry cranes, and other custom industrial material handling solutions. While there, Grayson played an instrumental role in executing a turnaround strategy which included reducing past due receivables by 71%, managing cash flow during a period of tight liquidity, renegotiating contract terms with customers and suppliers, and assisting in the recapitalization of the ownership structure. Previously, as a Principal at the $500 million private equity arm of a leading commercial bank holding company, he was a member of the team which structured and oversaw a portfolio consisting of private equity, venture capital, and fund-of-funds investments. Grayson started his career as a commercial loan underwriter. Grayson received his B.A. in History (high honors) from Dartmouth College and his M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology. Outside of work, Grayson enjoys being outdoors and active as much as possible, and likes sailing in the summer, hiking in the fall, and running throughout the year. For many years he has collected Asian art and artifacts and has been actively collecting Japanese woodblock prints since he was 12 years old. Both Grayson and his wife Lorraine enjoy cooking together and are always interested in trying out new recipes when they have the chance.
Follow Grayson Allen:
About RevBio: RevBio was started with one goal in mind—to end medicine’s 50-year search for a biocompatible bone adhesive.
C. Evan Ballantyne
Chief Financial Officer of OncXerna Therapeutics
C. Evan Ballantyne is the chief financial officer of [Agenus](https://www.crunchbase.com/organization/agenus), a biotechnology company that develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. Previously, he worked as the CEO of Synthetic Biologics. Ballantyne served as the CFO and executive vice president of Trovis Pharmaceuticals from 2006, before which he was the CFO of Knowledge Impact, ZymeQuest, Clinical Data, Velico Medical, Avalon Pharmaceuticals, and AcNielsen Corporation. Ballantyne holds a bachelor’s degree in political sciences and American history from the University of Western Ontario and a post-graduate degree in business administration from the University of Windsor.
Follow C. Evan Ballantyne:
About OncXerna Therapeutics: OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.
Ed Lafferty
General Partner & CFO of Saturn Partners
Follow Ed Lafferty:
About Chirpify, Saturn Partners: Since 1994, Saturn Partners has taken an active role in the formation and management of seed and early-stage technology companies.
Joanne Bryce
Chief Financial Officer of Disc Medicine
Follow Joanne Bryce:
About Disc Medicine, Speedy Packets: Disc Medicine is a hematology company
Phil Gardella
CFO of Vizgen
Phil Gardella is the Chief Financial Officer at Vizgen.
Follow Phil Gardella:
About Vizgen: Vizgen is a biotech company that develops solutions for next-generation spatially resolved, single-cell transcriptomics.
Sylvia Cheung
Chief Financial Officer of Oculis
Sylvia Cheung is the Chief Financial Officer at Anika Therapeutics since April 1, 2013. Sylvia brings to Anika a substantial number of years of financial and general management experience. Prior to her current position, Sylvia was the Vice President of Strategic Processes and previously, she served as the General Manager for the company’s Italian-based subsidiary, Anika S.r.l. Sylvia joined Anika as Controller in 2005. In addition to fulfilling wide-ranging financial responsibilities as Controller, Sylvia led the company’s integration of Anika S.r.l. subsequent to its acquisition in 2009. Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000, Sylvia worked for PricewaterhouseCoopers, LLP as an Audit Senior Associate. Sylvia holds a Bachelor of Business Administration degree in Accounting from the University of Massachusetts in Amherst, a Master’s degree in Business Administration from Boston University, and is a Certified Public Accountant (inactive).
Follow Sylvia Cheung:
About Oculis: Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Spencer Adams
Chief Financial Officer of Docent Health
Spencer Adams is the Chief Financial Officer at Docent Health.
Follow Spencer Adams:
About Docent Health: Helping health systems build and grow lasting patient relationships
Ken Mace
Chief Financial Officer of Alzheon
Follow Ken Mace:
About Alzheon: Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
Donald Notman
Chief Financial Officer of Ocular Therapeutix
Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Donald Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Donald Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Donald Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Donald Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
Follow Donald Notman:
About Ocular Therapeutix: Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.
Donald Notman
Chief Financial Officer of Ocular Therapeutix
Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Donald Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Donald Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Donald Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Donald Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
Follow Donald Notman:
About Ocular Therapeutix: Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.
Nathan Jorgensen
Chief Financial Officer of Vor Biopharma
Nathan Jorgensen is the Chief Financial Officer at Vor Biopharma.
Follow Nathan Jorgensen:
About Vor Biopharma: Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
William J. Kelly
Chief Financial Officer of Exosome Diagnostics
Mr. Kelly has over 20 years of financial management experience, including 13 years leading growing, international, publicly traded life science companies. Prior to joining Exosome Diagnostics, Mr. Kelly served in executive positions such as Chief Financial Officer of RepliGen Corporation and Corporate Controller of Haemonetics. In such roles, Mr. Kelly oversaw corporate financial operations, including several successful acquisitions. Mr. Kelly began his financial career as an auditor at leading financial firms Deloitte & Touche and Ernst and Young. Mr. Kelly is a Certified Public Accountant who holds an M.S./M.B.A. from Northeastern University and a B.A. in psychology from the College of the Holy Cross.
Follow William J. Kelly:
About Deloitte, Exosome Diagnostics: Exosome Diagnostics develops and commercializes blood-based cancer molecular diagnostics for patient stratification and disease monitoring.
Eric Shaff
CFO of Seres Therapeutics
Eric Shaff has over 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. He serves as the executive vice president and chief financial officer of [Seres Therapeutics](https://www.crunchbase.com/organization/seres-health#/entity), a therapeutics company engaged in the R&D of drugs for the treatment of microbiome diseases. Previously, Shaff was vice president of corporate finance at Momenta Pharmaceuticals, where he helped manage Momenta Pharmaceutical’s accounting, finance, planning, and procurement functions as well as contributing to Momenta Pharmaceutical’s investor relations efforts. Prior to joining Momenta Pharmaceuticals, he was the vice president of finance at Genzyme’s Rare Genetic Disease Division. Shaff held several positions in business unit finance, corporate finance, and corporate development at Genzyme. Before joining Genzyme, he worked in corporate finance at Pfizer and worked in investment banking for Broadview International. Shaff obtained his bachelor’s degree in political science and economics from the University of Pennsylvania and his MBA in finance from the Johnson Graduate School of Management at Cornell University.
Follow Eric Shaff:
About Seres Therapeutics: Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products.
Peter E Walcek
Vice President of Finance & Chief Financial Officer of Wentworth-Douglass Hospital
Follow Peter E Walcek:
About Wentworth-Douglass Hospital: Wentworth-Douglass Hospital is a nationally recognized, not-for-profit charitable health care organization.
Ian Bastow
CFO of Patients Know Best
Ian is a UK qualified accountant with experience in both blue-chip and start-up organisations in an international environment. Ian holds an MBA with Distinction from London Business School and has raised over $100m of funding for start-ups.
Follow Ian Bastow:
About Patients Know Best: Patients Know Best provide hospitals with personal health records software so that their patients can better manage their health.
R. Scott Areglado
SVP and Chief Financial Officer of Brainsway
Scott Areglado is the SVP and Chief Financial Officer at BrainsWay.
Follow R. Scott Areglado:
About Brainsway, iCAD: Brainsway’s patented breakthrough technology launches a new era in brain disorder treatment.
Gregory Fisichelli
Chief Financial Officer of ZwitterCo
Follow Gregory Fisichelli:
About ZwitterCo: ZwitterCo provides revolutionary membrane solutions for the treatment of highly-impaired wastewater.
Jim Waddell
Chief Financial Officer of Ageless Innovation
Follow Jim Waddell:
About Ageless Innovation: Ageless Innovation is a Health Care company.
David Francisco
Chief Financial Officer of Organogenesis
David Francisco is the Chief Financial Officer at Organogenesis.
Follow David Francisco:
About Organogenesis: Organogenesis Inc. is a regenerative medicine company.
Michael Kaswan
Chief Financial Officer of Cognoptix
Michael Kaswan is the Chief Financial Officer at Cognoptix.
Follow Michael Kaswan:
About Cognoptix, Dune Medical Devices: Cognoptix develops non-invasive eye tests for the early diagnosis of alzheimer disease.